Learn peptides step by step

July 2026 Peptide Research Snapshot: Retatrutide, BPC-157, MOTS-C, GHK-Cu, and Tesamorelin

The peptide space is loud. This snapshot cuts through the noise and focuses on the compounds that still have real biology behind them.

July 2026 Peptide Research Signals: The 5 Compounds Worth Watching

The most useful peptide research is not the loudest. It is the stuff that changes the question from 'does it work?' to 'who does it help, for what outcome, and with what tradeoffs?'

Retatrutide and Body Composition: Why the Real Story Is Adherence, Not Just Scale Weight

The best metabolic tools do more than move the scale. They change how easy it is to follow the plan on day 3, day 30, and day 300.

Retatrutide and Food Noise: Why Appetite Control Changes Adherence

The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.

Retatrutide and Visceral Fat: Why the Scale Misses the Real Signal

Scale weight is noisy. If you are using retatrutide, waist trend, body composition, protein intake, and strength matter more than a single weigh-in.

12m

InsightsIntermediate

PeptIQ H1 2026 Report: What Thousands of Real Peptide Logs Reveal

Retatrutide dominates H1 logging, the Wolverine stack is real, and quick-log onboarding predicts who actually tracks. Our first semi-annual data report from thousands of real peptide logs.

Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means

Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.

Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds

Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?

Amylin and GLP-1: The Next Wave of Metabolic Peptides

The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.

Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data

The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.

GLP-1 Discontinuation: How to Maintain Weight Loss After Stopping

A 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.

Viral Peptide Stack Transformations: How to Read the Evidence

Stack stories spread fast because they are visual and emotional. The smarter move is not to copy the protocol. It is to ask better evidence questions.

Health Canada Peptide Warning: What Buyers Should Know

Health Canada's 2026 public advisory names unauthorized injectable peptides sold online and explains why product quality, legal status, and medical supervision matter.

Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch

Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.

GLP-1 Nutrition Strategy: Protein, Muscle, and Labs

New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.

Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide

The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.

Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means

31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.

GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps

Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.

Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard

New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.

GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found

You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.

Retatrutide Not Working for Weight Loss? Here's What to Check

You've been on Retatrutide for 4-6 weeks and the scale hasn't budged. Before you give up or double your dose, here are the real reasons Reta might not be 'working' — and what to actually do about it.

MOTS-C After Stopping GLP-1 Agonists: Dosing and Protocol Guide

Finished your GLP-1 cycle and want to maintain metabolic momentum? MOTS-C is one of the most effective peptides for supporting fat oxidation and energy during GLP-1 off-cycles. Here's how to dose and time it.

Stacking Tesamorelin and MOTS-C with Retatrutide: A Complete Protocol Guide

Already on Reta and ready to add compounds? Here's how to stack Tesamorelin and MOTS-C with Retatrutide for maximum fat loss and recomp.

Switching from Tirzepatide to Retatrutide: The Complete Transition Guide

Already on tirzepatide and considering retatrutide? Here's exactly how to make the switch—starting doses based on your current Tirz level, what the glucagon component changes, and how to avoid common transition mistakes.

Retatrutide Dosing for Beginners: Your First 12-Week Titration Schedule

Retatrutide is one of the most powerful GLP-1/GIP/glucagon receptor agonists available. But starting at the wrong dose — or jumping up too fast — is the #1 beginner mistake. Here's the complete titration roadmap.

PolicyAdvanced

Oral GLP-1s Are Here: What the Foundayo FDA Approval Means for the Peptide Community

For years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.

The Complete GLP-1 + Mitochondrial Fat Loss Stack: Reta, MOTS-C, SS-31, AOD, and SLU-PP-332

Running Retatrutide and wondering what to add? This guide breaks down how MOTS-C, SS-31, AOD-9604, and SLU-PP-332 layer onto a GLP-1 protocol — and why they're not redundant.

5-Amino-1MQ: The NNMT Inhibitor That Stacks With GLP-1s and MOTS-C

Most fat-loss compounds either suppress appetite or boost energy expenditure. 5-Amino-1MQ does something different — it blocks the enzyme that burns through your NAD+ and keeps fat cells from ever getting broken down. Here's why it stacks so well with Reta and MOTS-C.

Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss

Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.

Why Your Weight Isn't Moving on Retatrutide (And What to Do About It)

Hitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.

AOD-9604: The HGH Fragment That Targets Fat Without the Side Effects

AOD-9604 is a synthetic fragment of human growth hormone designed specifically to stimulate fat breakdown without the glucose or IGF-1 side effects of full HGH. Here's how it works and who it's for.

Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard

Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.

11m

Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1

A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.

Retatrutide: How to Reconstitute and Take Your First Dose

Everything you need to know before your first retatrutide injection — reconstitution math, dose calculations, injection technique, and what to expect if you have prior GLP-1 sensitivity.

Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed

Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.

Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows

TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.

The Science of Retatrutide: How GLP-1/GIP/Glucagon Triple Agonists Work

Retatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.

How Retatrutide Works: The Science Behind the Triple-Receptor Agonist

Retatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.

Start hereBeginner

Retatrutide Beginner's Guide: Reconstitution, Dosing & Getting Started

New to retatrutide? This guide covers everything: how much BAC water to add, dose calculations for common vial sizes, starting doses, and titration schedules for safe, effective results.

Why Retatrutide Preserves Muscle Better Than Tirzepatide

Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.

12m

Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows

Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.

Retatrutide Phase 3 Results: What the Clinical Data Tells Us

New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.

Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial

Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.

Retatrutide: The Triple-Action Weight Loss Peptide Explained

Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.

12m

GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy

GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.